Loading...
GNS logo

Genus plcLSE:GNS Rapporto sulle azioni

Cap. di mercato UK£1.6b
Prezzo delle azioni
UK£23.56
UK£31.63
25.5% sottovalutato sconto intrinseco
1Y17.5%
7D-2.2%
Valore del portafoglio
​
Vista

Genus plc

Report azionario LSE:GNS

Capitalizzazione di mercato: UK£1.6b

Genus (GNS) Panoramica del titolo

Genus plc produce e vende genetica animale agli agricoltori di Nord America, America Latina, Regno Unito, resto d'Europa, Medio Oriente, Russia, Africa e Asia. Maggiori dettagli

GNS analisi fondamentale
Punteggio fiocco di neve
Valutazione1/6
Crescita futura0/6
Prestazioni passate1/6
Salute finanziaria5/6
Dividendi0/6

Premi

È diventato redditizio quest'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 34.1%

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 1.1% all'anno per i prossimi 3 anni

Grandi elementi una tantum che incidono sui risultati finanziari


GNS Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 64.4% sottovalutato sconto intrinseco
5419.8%Revenue growth p.a.
6.2k
18
0
126
3mo ago

Concorrenti di Genus plc

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Genus
Prezzi storici delle azioni
Prezzo attuale dell'azioneUK£23.56
Massimo di 52 settimaneUK£32.29
Minimo di 52 settimaneUK£18.90
Beta0.94
Variazione di 1 mese-3.84%
Variazione a 3 mesi-25.44%
Variazione di 1 anno17.51%
Variazione a 3 anni-15.07%
Variazione a 5 anni-53.39%
Variazione dall'IPO1,645.19%

Notizie e aggiornamenti recenti

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.

Recent updates

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.

GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside

Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.

GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook

Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.

GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential

Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.

GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk

Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.

Calculating The Fair Value Of Genus plc (LON:GNS)

Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)

GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks

Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.

GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks

Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.

GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns

Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.

Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Estimating The Fair Value Of Genus plc (LON:GNS)

Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)

Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued

Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
User avatar

Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position

Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

The Price Is Right For Genus plc (LON:GNS)

Jun 16
The Price Is Right For Genus plc (LON:GNS)

Estimating The Fair Value Of Genus plc (LON:GNS)

Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

Mar 25
Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Nov 03
We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Rendimenti per gli azionisti

GNSGB BiotechsGB Mercato
7D-2.2%-0.8%-0.2%
1Y17.5%16.7%19.7%

Ritorno vs Industria: GNS ha superato il UK Biotechs che ha restituito 16.7 % nell'ultimo anno.

Rendimento vs Mercato: GNS ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 19.7 % nell'ultimo anno.

Volatilità dei prezzi

Is GNS's price volatile compared to industry and market?
GNS volatility
GNS Average Weekly Movement5.7%
Biotechs Industry Average Movement9.9%
Market Average Movement5.6%
10% most volatile stocks in GB Market11.5%
10% least volatile stocks in GB Market3.2%

Prezzo delle azioni stabile: GNS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato UK.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di GNS è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19943,190JK Kokkewww.genusplc.com

Genus plc produce e vende genetica animale agli agricoltori di Nord America, America Latina, Regno Unito, resto d'Europa, Medio Oriente, Russia, Africa e Asia. L'azienda opera attraverso tre segmenti: Genus PIC, Genus ABS e Genus Ricerca e Sviluppo. Offre sperma ed embrioni di tori da latte e da carne con i marchi Genus e Bovec; sperma e carne suina da riproduzione, nonché servizi tecnici e consulenza con il marchio PIC.

Genus plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Genus con la sua capitalizzazione di mercato?
GNS statistiche fondamentali
Capitalizzazione di mercatoUK£1.58b
Utili (TTM)UK£47.50m
Ricavi(TTM)UK£672.00m
33.2x
Rapporto P/E
2.3x
Rapporto P/S

GNS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GNS Conto economico (TTM)
RicaviUK£672.00m
Costo del fatturatoUK£402.40m
Profitto lordoUK£269.60m
Altre speseUK£222.10m
UtiliUK£47.50m

Ultimi utili riportati

Dec 31, 2025

Prossima data di guadagno

Sep 10, 2026

Utile per azione (EPS)0.71
Margine lordo40.12%
Margine di profitto netto7.07%
Rapporto debito/patrimonio netto46.4%

Come si è comportato GNS nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.4%
Rendimento attuale del dividendo
46%
Rapporto di remunerazione

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/01 16:45
Prezzo dell'azione a fine giornata2026/05/01 00:00
Utili2025/12/31
Utili annuali2025/06/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Genus plc è coperta da 17 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Robert ChantryBerenberg
Matthew LloydBNP Paribas
Alexander JonesBofA Global Research